PARP Inhibitor Combinations in Prostate Cancer: Expanding Treatment Options to Broader Patient Populations

Download All
Learn how experts incorporate the newest evidence from ASCO 2021 on PARP inhibitor–based combinations into optimal management of prostate cancer with an on-demand webcast from a live webinar plus an expert commentary, podcast, and downloadable slidesets with ExpressPoints slides.
Charles J. Ryan, MD
Program Director
person default
Wassim Abida, MD, PhD
Joaquin Mateo, MD, PhD

On-Demand Webcast

Learn about the underlying rationale for PARP combination approaches in prostate cancer and discover the many ongoing clinical trials of PARP inhibitors combined with AR-directed therapy, immunotherapy, or other targeted agents.

Charles J. Ryan, MD
Program Director
person default Wassim Abida, MD, PhD Joaquin Mateo, MD, PhD
Physicians: maximum of 0.75 AMA PRA Category 1 Credits Released: July 7, 2021 Expired: July 6, 2022
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
AstraZeneca
Merck Sharp & Dohme Corp.
Pfizer, Inc.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings